Efficacy and Safety of Drug-Coated Balloon in the Treatment of Coronary Chronic Total Occlusion
LIU Hengdao
ZHANG Yubin
LIU Ting
GU Heping
XING Junhui
ZHAO Junwei
SONG Ruipeng
ZHAO Yanyan
TAO Hailong
Abstract：Objective To investigate the efficacy and safety of drug-coated balloon(DCB)dilatation in the treatment of coronary chronic total occlusion(CTO)lesions.Methods A total of 100 patients were enrolled,who were diagnosed with de novo CTO by coronary angiography and undergoing percutaneous coronary intervention(PCI)at the First Affiliated Hospital of Zhengzhou University from March 2018 to January 2021.Based on the treatment strategy,patients were divided into drug-eluting stent(DES)group(52 cases)and DCB group(48 cases).The clinical baseline data,coronary angiography data,and major adverse cardiovascular events(MACE)were compared between the two groups of patients.Results The median follow-up durations for the DCB group and the DES group were 6 months and 10 months,respectively.There were no statistical differences in baseline clinical characteristics between the two groups.Efficacy analysis revealed that compared to the DES group,the DCB group had a smaller minimum lumen diameter(MLD)immediately after the procedure(P＜0.001)and a higher degree of diameter stenosis(DS)(P＜0.05).During follow-up,there were no statistical differences in these parameters between the two groups(P＞0.05).The DCB group exhibited a smaller late lumen loss(LLL)diameter,with a statistical difference(P＜0.001).Immediately after the procedure,one patient in the DCB group occurred dissection and underwent salvage stent therapy.During follow-up,7 patients(14.58％)in the DCB group experienced restenosis,while 5 patients(9.62％)in the DES group experienced restenosis,and there was no statistical difference in restenosis rate between the two groups(P＞0.05).There were also no statistical differences in MACE rates between the two groups during hospitalization and follow-up(P＞0.05).Kaplan-Meier survival analysis demonstrated that the choice of treatment strategy had no statistically significant impact on the risk of MACE(P＞0.05).Conclusion Compared to DES,DCB demonstrates relatively satisfactory efficacy and safety in treating de novo CTO lesions and is significantly superior to DES in terms of late lumen loss.Therefore,DCB can be considered a viable alternative interventional strategy for de novo CTO lesions.
Keywords：coronary chronic total occlusionpercutaneous coronary interventiondrug-coated balloondrug-eluting stent
Publication Date：2025-04-13
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：5( 1180-1184 )